Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment.
BACKGROUND
The optimal endoscopic approach to the drainage of malignant hilar strictures remains controversial, especially with regard to the extent of desirable drainage and unilateral or bilateral stenting.


OBJECTIVE
To identify useful criteria for predicting successful endoscopic drainage.


METHODS
Retrospective 2-center study in the greater Paris area in France.


METHODS
A total of 107 patients who had undergone endoscopic stenting for hilar tumors Bismuth type II, III, or IV and a set of contemporaneous cross-sectional imaging data available.


METHODS
The relative volumetry of the 3 main hepatic sectors (left, right anterior, and right posterior) was assessed on CT scans. The liver volume drained was estimated and classified into 1 of 3 classes: less than 30%, 30% to 50%, and more than 50% of the total liver volume.


METHODS
The primary outcome was effective drainage, defined as a decrease in the bilirubin level of more than 50% at 30 days after drainage. Secondary outcomes were early cholangitis rate and survival.


RESULTS
The main factor associated with drainage effectiveness was a liver volume drained of more than 50% (odds ratio 4.5, P = .001), especially in Bismuth III strictures. Intubating an atrophic sector (<30%) was useless and increased the risk of cholangitis (odds ratio 3.04, P = .01). A drainage > 50% was associated with a longer median survival (119 vs 59 days, P = .005).


CONCLUSIONS
Heterogeneous population and volume assessment methodology to improve in further prospective studies.


CONCLUSIONS
Draining more than 50% of the liver volume, which frequently requires bilateral stent placement, seems to be an important predictor of drainage effectiveness in malignant, especially Bismuth III, hilar strictures. A pre-ERCP assessment of hepatic volume distribution on cross-sectional imaging may optimize endoscopic procedures.
Vienne
Ariane
A
Gastroenterology, Saint Antoine Hospital, Paris, France.
Hobeika
Ehlam
E
Gouya
Hervé
H
Lapidus
Nathanael
N
Fritsch
Jacques
J
Choury
André Daniel
AD
Chryssostalis
Ariane
A
Gaudric
Marianne
M
Pelletier
Gilles
G
Buffet
Catherine
C
Chaussade
Stanislas
S
Prat
Frédéric
F
D000368:Aged; D001284:Atrophy; D001650:Bile Duct Neoplasms / Q000150:complications; D001653:Bile Ducts, Intrahepatic; D001663:Bilirubin / Q000097:blood; D018281:Cholangiocarcinoma; D002760:Cholangiopancreatography, Endoscopic Retrograde; D002761:Cholangitis / Q000453:epidemiology / Q000601:surgery; D002779:Cholestasis / Q000401:mortality / Q000601:surgery*; D004067:Digestive System Neoplasms / Q000150:complications* / Q000473:pathology; D004322:Drainage / Q000379:methods*; D016145:Endoscopy, Digestive System; D005260:Female; D005706:Gallbladder Neoplasms / Q000150:complications; D006801:Humans; D053208:Kaplan-Meier Estimate; D008099:Liver / Q000000981:diagnostic imaging / Q000473:pathology*; D008113:Liver Neoplasms / Q000150:complications / Q000556:secondary; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009929:Organ Size; D011474:Prosthesis Design; D012189:Retrospective Studies; D015607:Stents; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D001663:Bilirubin